How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?

This is always a point of discomfort among providers, but can actually be made quite easy.

BTK inhibitors have known anti-platelet effects similar to low-dose aspirin. Consequently, if the surgeon would hold aspirin for the planned procedure, I generally recommend that we hold the BTK inhibitor for 3...